TIRZEPATIDE
Information current as at: 1 July 2026
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Mounjaro® Mounjaro® KwikPen®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Submission sponsor:
- ELI LILLY AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Type 2 diabetes mellitus
- Listing requested:
- Please see PSD for more information
- Funding program:
- PBS General Schedule
- Request authority level:
- Please see PSD for more information
- PBAC Submission type:
- New PBS listing (Matters arising/Matters outstanding)
- Comment:
- --
- Other PBAC consideration:
Progress Details
-
Submission received for: - March 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 02/04/2025 and close 28/05/2025 (see PBS Website)
-
PBAC meeting: - Held on 11/03/2026
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
The PBAC recommended the listing of tirzepatide (Mounjaro®) for the treatment of adults with inadequately controlled type 2 diabetes mellitus. The PBAC recalled input from individuals, health care professionals and organisations in relation to the July 2025 submission, noting benefits of tirzepatide use including improved daily blood glucose readings, improved HbA1c results and weight loss and noting the high cost of tirzepatide making it difficult for some people to access. The PBAC acknowledged the clinical need for additional effective treatment options for people with type 2 diabetes mellitus, noting that a proportion of patients do not achieve adequate glycaemic control with currently PBS‑listed therapies. The PBAC noted that tirzepatide is currently available through the private market and considered that PBS listing would improve equity of access, particularly for patients for whom cost may be a barrier.
The PBAC noted that it had previously considered tirzepatide at its July 2023, November 2024 and July 2025 meetings, and that the current submission included revisions in response to the PBAC deferring making a recommendation for tirzepatide at its July 2025 meeting. These revisions included changes to the proposed pricing, updated estimates of the number of patients that would use tirzepatide and a revised approach to managing financial risks.
The PBAC considered tirzepatide 10 mg and 15 mg strengths to be cost‑effective, and tirzepatide 5 mg would be cost-effective with a reduced price. The PBAC accepted the sponsor’s revised estimates of the number of patients that would use tirzepatide, considering these to be reasonable for the purposes of the submission, while acknowledging ongoing uncertainties related to changes in the market dynamics and supply constraints. The PBAC accepted the supply of tirzepatide under normal PBS arrangements and considered this appropriate to support equitable access through community pharmacy. The PBAC requested that arrangements for managing financial risks be progressed separately between the sponsor and the Department.